Moderna, Inc. (NASDAQ:MRNA) Receives $90.22 Average Price Target from Brokerages

Shares of Moderna, Inc. (NASDAQ:MRNA) have been given a consensus recommendation of “Hold” by the twenty-two research firms that are currently covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a sell recommendation, thirteen have assigned a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $84.00.

MRNA has been the subject of several research reports. HSBC upgraded shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 price objective for the company in a research report on Monday. JPMorgan Chase & Co. lowered their price objective on shares of Moderna from $70.00 to $59.00 and set an “underweight” rating for the company in a research report on Monday, November 4th. UBS Group lowered their price objective on shares of Moderna from $140.00 to $108.00 and set a “buy” rating for the company in a research report on Thursday, October 24th. Needham & Company LLC restated a “hold” rating on shares of Moderna in a report on Friday, November 8th. Finally, TD Cowen lowered their target price on shares of Moderna from $70.00 to $60.00 and set a “hold” rating for the company in a report on Friday, September 13th.

Moderna Price Performance

Shares of NASDAQ:MRNA opened at $36.94 on Monday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39. The firm has a fifty day moving average price of $56.98 and a 200 day moving average price of $95.46. Moderna has a fifty-two week low of $35.80 and a fifty-two week high of $170.47. The firm has a market cap of $14.22 billion, a price-to-earnings ratio of -6.41 and a beta of 1.69.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The firm had revenue of $1.90 billion during the quarter, compared to analyst estimates of $1.25 billion. During the same quarter in the prior year, the business earned ($1.39) earnings per share. Moderna’s revenue for the quarter was up 3.8% on a year-over-year basis. As a group, sell-side analysts expect that Moderna will post -9.43 earnings per share for the current fiscal year.

Insider Buying and Selling at Moderna

In other Moderna news, CFO James M. Mock sold 715 shares of Moderna stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the sale, the chief financial officer now directly owns 9,505 shares in the company, valued at approximately $571,440.60. The trade was a 7.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In the last ninety days, insiders sold 2,930 shares of company stock worth $217,170. Company insiders own 15.20% of the company’s stock.

Hedge Funds Weigh In On Moderna

Several institutional investors have recently made changes to their positions in the company. State Street Corp increased its holdings in shares of Moderna by 12.1% during the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company’s stock valued at $1,125,899,000 after purchasing an additional 1,823,276 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Moderna by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company’s stock valued at $470,670,000 after purchasing an additional 178,115 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Moderna by 21.0% during the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock valued at $349,166,000 after purchasing an additional 906,114 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Moderna by 0.5% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,890,812 shares of the company’s stock valued at $260,023,000 after purchasing an additional 19,819 shares in the last quarter. Finally, Capital World Investors increased its holdings in shares of Moderna by 0.5% during the 1st quarter. Capital World Investors now owns 3,648,117 shares of the company’s stock valued at $388,743,000 after purchasing an additional 18,728 shares in the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.